Drugs / buformin
buformin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01584232 Background | Apr 2012 → Jul 2013 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | buformin | “OAMs included sulfonylureas (SU; glibenclamide, gliclazide, or glimepiride) and/or biguanides (BG; metformin or buformin).” NCT01584232 ↗ |
| Known as | Buformin hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL39736 ↗ |
| Known as | Buformina | ChEMBL registry synonym — accepted as the source's own label CHEMBL39736 ↗ |
| Known as | Buformine | ChEMBL registry synonym — accepted as the source's own label CHEMBL39736 ↗ |
| Modality | Small molecule | — CHEMBL39736 ↗ |